Table 2.

Studies included in the systematic review

MicroRNA	Cancer type	Biofluid type	Deregulation	Author	Reference
miR-125b	Bladder cancer	Urine	↓ tumors vs controls	Zhang et al.	46
			↓ high-grades vs low-grades
	Uveal Melanoma	Plasma	↑tumors vs controls	Achberger et al.	47
	Advanced Melanoma	Seruma	↓tumors vs controls	Alegre et al.	48
	Ewing’s sarcoma	Serum	↓ tumors vs controls	Nie et al.	49
	Breast cancer	Serum	↑ late stages vs controls	Wang et al.	50
			↑ late stages vs early stages
	Breast cancer	Urine	↓ tumors vs controls	Erbes et al.	51
	Breast cancer	Serum	↑ tumors vs controls	Mar-Aguilar et al.	52
	Breast cancer	Serum	↑ tumors vs controls	Matamala et al.	53
	Non-small-cell lung cancer	Serum	↑ tumorsvs controls	Yuxia et al.	54
			↑ late stages vs early stages
	Non-small-cell lung cancer	Plasma	↑ tumors vs controls	Zhao et al.	55
			↑ late stages vs early stages
	Diffuse large B-cell lymphoma	Serum	↑ tumors vs controls	Yuan et al.	56
	Laryngeal squamous cell carcinoma	Plasma	↓ tumors vs controls	Ayaz et al.	57
	Glioma	Serum	↓ tumors vs controls	Wei et al.	32
			↓ high-grades vs low-grades
	Colorectal neoplasia	Serum	↑ tumors vs controls	Yamada et al.	58
miR-497	Bladder cancer	Plasma	↓ tumors vs controls	Du et al.	59
	Astrocytoma	Serum	↓ tumors vs controls	Yang et al.	26
	Nasopharyngeal carcinoma	Plasma	↓ tumors vs controls	Wang et al.	60
	Prostate cancer	Serum	↓ tumors vs controls	Kong et al.	61
	Cervical cancer	Serum	↑ tumors vs controls	Zhang et al.	62

^aExosomal fraction only